Testing two antibody drugs for lymphoma that came back
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older) and agree to the study, or your legal representative agrees
- You can provide a recent biopsy tissue sample (or an allowed exception is approved)
- Your lymphoma is DLBCL or follicular lymphoma grade 3B, confirmed by a pathology review at the study site
- Your cancer has returned or is not responding after at least one prior treatment, with at least one measurable spot on scans
- Your tumor tissue tests positive for both CD19 and CD20, and your body can handle treatment (blood tests and liver/kidney levels meet limits)
- You have not previously received loncastuximab tesirine, mosunetuzumab, or other CD20-targeting bispecific antibodies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This Phase 2 study tests loncastuximab tesirine, a medicine that targets lymphoma cells, in people with marginal zone lymphoma that came back or did not respond to prior treatment. It aims to see how well the treatment can control the disease and shrink lymphoma in the body.
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
This trial tests adding a drug called mosunetuzumab to standard chemotherapy for people with certain aggressive B-cell lymphomas. It aims to see if the combination works better than chemo alone.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.